These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 23441892)
1. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Beaton MD; Chakrabarti S; Levstik M; Speechley M; Marotta P; Adams P Aliment Pharmacol Ther; 2013 Apr; 37(7):720-9. PubMed ID: 23441892 [TBL] [Abstract][Full Text] [Related]
2. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Valenti L; Fracanzani AL; Dongiovanni P; Bugianesi E; Marchesini G; Manzini P; Vanni E; Fargion S Am J Gastroenterol; 2007 Jun; 102(6):1251-8. PubMed ID: 17391316 [TBL] [Abstract][Full Text] [Related]
3. Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease. Beaton MD; Chakrabarti S; Adams PC Ann Hepatol; 2014; 13(3):353-6. PubMed ID: 24756010 [TBL] [Abstract][Full Text] [Related]
4. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. Valenti L; Dongiovanni P; Fargion S World J Gastroenterol; 2012 Aug; 18(29):3782-6. PubMed ID: 22876027 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. Valenti L; Fracanzani AL; Dongiovanni P; Rovida S; Rametta R; Fatta E; Pulixi EA; Maggioni M; Fargion S World J Gastroenterol; 2014 Mar; 20(11):3002-10. PubMed ID: 24659891 [TBL] [Abstract][Full Text] [Related]
7. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Adams LA; Crawford DH; Stuart K; House MJ; St Pierre TG; Webb M; Ching HL; Kava J; Bynevelt M; MacQuillan GC; Garas G; Ayonrinde OT; Mori TA; Croft KD; Niu X; Jeffrey GP; Olynyk JK Hepatology; 2015 May; 61(5):1555-64. PubMed ID: 25524401 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hyperferritinemia. Beaton MD; Adams PC Ann Hepatol; 2012; 11(3):294-300. PubMed ID: 22481446 [TBL] [Abstract][Full Text] [Related]
10. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Hagström H; Nasr P; Bottai M; Ekstedt M; Kechagias S; Hultcrantz R; Stål P Liver Int; 2016 Nov; 36(11):1688-1695. PubMed ID: 27064133 [TBL] [Abstract][Full Text] [Related]
11. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Lecube A; Hernández C; Simó R Diabetes Metab Res Rev; 2009 Jul; 25(5):403-10. PubMed ID: 19444865 [TBL] [Abstract][Full Text] [Related]
12. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Wong VW; Chan HL; Hui AY; Chan KF; Liew CT; Chan FK; Sung JJ Aliment Pharmacol Ther; 2004 Jul; 20(1):45-9. PubMed ID: 15225170 [TBL] [Abstract][Full Text] [Related]
13. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Yano M; Hayashi H; Wakusawa S; Sanae F; Takikawa T; Shiono Y; Arao M; Ukai K; Ito H; Watanabe K; Yoshioka K Am J Gastroenterol; 2002 Jan; 97(1):133-7. PubMed ID: 11808937 [TBL] [Abstract][Full Text] [Related]
14. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730 [TBL] [Abstract][Full Text] [Related]
15. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. Chandok N; Minuk G; Wengiel M; Uhanova J J Gastrointestin Liver Dis; 2012 Mar; 21(1):53-8. PubMed ID: 22457860 [TBL] [Abstract][Full Text] [Related]
16. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. Chan WK; Ida NH; Cheah PL; Goh KL J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399 [TBL] [Abstract][Full Text] [Related]
17. How should hyperferritinaemia be investigated and managed? Ong SY; Nicoll AJ; Delatycki MB Eur J Intern Med; 2016 Sep; 33():21-7. PubMed ID: 27346296 [TBL] [Abstract][Full Text] [Related]
18. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. Jin YJ; Kim KM; Hwang S; Lee SG; Ha TY; Song GW; Jung DH; Kim KH; Yu E; Shim JH; Lim YS; Lee HC; Chung YH; Lee Y; Suh DJ J Gastroenterol Hepatol; 2012 Aug; 27(8):1341-7. PubMed ID: 22554085 [TBL] [Abstract][Full Text] [Related]
19. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085 [TBL] [Abstract][Full Text] [Related]